DelveInsight’s “Bullous Keratopathy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Bullous Keratopathy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Bullous Keratopathy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Bullous Keratopathy: An Overview
According to the Cornea Research Foundation of America (2022), Bullous keratopathy is a condition in which the cornea becomes permanently swollen. This occurs because the inner layer of the cornea, the endothelium, has been damaged and is not pumping fluid properly. The cause of endothelial damage could be trauma, glaucoma, or inflammation after eye surgery.
Treatment by an ophthalmologist is required and includes topical dehydrating agents (e.g., hypertonic [5%] sodium chloride drops and ointment), intraocular pressure–lowering agents, occasional short-term use of therapeutic soft contact lenses for some mild to moderate cases, and treatment of any secondary microbial infection. Corneal transplantation is usually curative when these treatments are inadequate to restore functional vision.
Bullous Keratopathy Market Key Facts
According to the American Academy of Ophthalmology (2022), it is estimated that 1-2 % of people undergoing cataract surgery will develop persistent post-operative edema. Old surgical techniques and intraocular lens designs were associated with higher numbers of postoperative corneal edema. Currently, pre-operative endothelial cell count and surgical trauma are the most important factors for developing PBK.
A cross-sectional national survey was conducted in Japan for 963 eyes with bullous keratopathy between 1999 and 2001 by members of the Japan Cornea Society. Demographic characteristics, type of surgery, complications, and postoperative outcomes were analyzed. Bullous keratopathy accounted for 24.2% (963 eyes) of total keratoplasties performed during the period (Shimazaki et al., 2007).
Bullous Keratopathy Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Bullous Keratopathy market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Bullous Keratopathy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Bullous Keratopathy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Bullous Keratopathy Epidemiology, Segmented as –
Total Prevalent Cases of Bullous Keratopathy in the 7MM [2019-2032]
Age-specific Prevalent Cases of Bullous Keratopathy in the 7MM [2019–2032]
Cause-specific Prevalent Cases of Bullous Keratopathy in the 7MM [2019–2032]
Gender-specific Prevalent Cases of Bullous Keratopathy in the 7MM [2019–2032]
Bullous Keratopathy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Bullous Keratopathy market or expected to be launched during the study period. The analysis covers the Bullous Keratopathy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Bullous Keratopathy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Bullous Keratopathy Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/bullous-keratopathy-market
The Leading Companies in the Bullous Keratopathy Therapeutics Market Include:
Cellusion
Emmecell
And Many Other
Bullous Keratopathy Therapies Covered in the Report Include:
EO2002: Emmecell
CLS001: Cellusion
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Bullous Keratopathy Competitive Intelligence Analysis
4. Bullous Keratopathy Market Overview at a Glance
5. Bullous Keratopathy Disease Background and Overview
6. Bullous Keratopathy Patient Journey
7. Bullous Keratopathy Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Bullous Keratopathy Treatment Algorithm, Current Treatment, and Medical Practices
9. Bullous Keratopathy Unmet Needs
10. Key Endpoints of Bullous Keratopathy Treatment
11. Bullous Keratopathy Marketed Products
12. Bullous Keratopathy Emerging Drugs and Latest Therapeutic Advances
13. Bullous Keratopathy Seven Major Market Analysis
14. Attribute Analysis
15. Bullous Keratopathy Market Outlook (In US, EU5, and Japan)
16. Bullous Keratopathy Access and Reimbursement Overview
17. KOL Views on the Bullous Keratopathy Market
18. Bullous Keratopathy Market Drivers
19. Bullous Keratopathy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
